HealthDay News — Vitamin D supplementation does not prevent statin-associated muscle symptoms (SAMS) or reduce statin discontinuation, according to a study published online November 23 in JAMA Cardiology.

Mark A. Hlatky, MD, from the Stanford University School of Medicine in California, and colleagues randomly assigned men aged 50 years and older and women aged 55 years and older to daily cholecalciferol (2000 international units; 1033 patients) or placebo (1050 patients).

The researchers found that during 4.8 years of follow-up, SAMS were reported by 31% of participants assigned to both groups (adjusted odds ratio, 0.97; 95% CI, 0.80 to 1.18; P =.78). Statin discontinuation was also similar between the groups (adjusted odds ratio, 1.04; 95% CI, 0.80 to 1.35; P =.78). Results remained consistent across pretreatment 25-hydroxyvitamin D levels. For participants with vitamin D levels less than 20 ng/mL and less than 30 ng/mL, SAMS were reported by 33 and 27% of vitamin D-assigned participants, respectively, and 35 and 30% of placebo-assigned participants, respectively.

“This suggests that vitamin D lacks a clinically important effect in preventing SAMS,” the authors write.

One author disclosed financial ties to Pharmavite, which provided the vitamin D and placebo for the study.

Abstract/Full Text